4/18
10:10 pm
tak
Progressive Familial Intrahepatic Cholestasis Treatment Market Projected to Reach $156.14 million by 2030 - Exclusive Report by 360iResearch [Yahoo! Finance]
Low
Report
Progressive Familial Intrahepatic Cholestasis Treatment Market Projected to Reach $156.14 million by 2030 - Exclusive Report by 360iResearch [Yahoo! Finance]
4/18
07:08 pm
tak
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease [Yahoo! Finance]
Low
Report
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease [Yahoo! Finance]
4/18
07:00 pm
tak
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
Low
Report
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
4/16
01:32 pm
tak
ISPE Announces 2024 Facility of the Year Awards (FOYA) Category Winners [Yahoo! Finance]
Low
Report
ISPE Announces 2024 Facility of the Year Awards (FOYA) Category Winners [Yahoo! Finance]
4/16
01:20 pm
tak
ISPE Announces 2024 Facility of the Year Awards (FOYA) Category Winners
Low
Report
ISPE Announces 2024 Facility of the Year Awards (FOYA) Category Winners
4/15
08:13 am
tak
Neurvati Neurosciences Announces Appointment of Deborah Dunsire, MD, as Member and Chair of Company Board of Directors [Yahoo! Finance]
Low
Report
Neurvati Neurosciences Announces Appointment of Deborah Dunsire, MD, as Member and Chair of Company Board of Directors [Yahoo! Finance]
4/12
11:36 am
tak
Inflammatory Bowel Diseases (IBD) Drugs market is projected to grow at a CAGR 6.2% by 2034: Visiongain [Yahoo! Finance]
Low
Report
Inflammatory Bowel Diseases (IBD) Drugs market is projected to grow at a CAGR 6.2% by 2034: Visiongain [Yahoo! Finance]
4/9
01:12 pm
tak
Excessive Daytime Sleepiness Market is Projected to Boost at a Moderate Growth Rate by 2032, Predicts DelveInsight | Key Companies in the Market - Avadel Pharmaceutical, Axsome Therapeutic, Theranexus, XWPharma, Takeda Pharmaceutical [Yahoo! Finance]
Low
Report
Excessive Daytime Sleepiness Market is Projected to Boost at a Moderate Growth Rate by 2032, Predicts DelveInsight | Key Companies in the Market - Avadel Pharmaceutical, Axsome Therapeutic, Theranexus, XWPharma, Takeda Pharmaceutical [Yahoo! Finance]
4/8
08:00 am
tak
Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food
Low
Report
Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food
4/5
08:08 am
tak
PanTher Therapeutics Announces Appointment of John Edwards as Executive Chair of the Board of Directors [Yahoo! Finance]
Low
Report
PanTher Therapeutics Announces Appointment of John Edwards as Executive Chair of the Board of Directors [Yahoo! Finance]
4/4
06:34 am
tak
Gastrointestinal Therapeutics and Diagnostics Technology and Global Markets Report 2024: Revenue Data 2020-2022, Estimates for 2023, Forecasts for 2024, and CAGR Projections through 2028 [Yahoo! Finance]
Low
Report
Gastrointestinal Therapeutics and Diagnostics Technology and Global Markets Report 2024: Revenue Data 2020-2022, Estimates for 2023, Forecasts for 2024, and CAGR Projections through 2028 [Yahoo! Finance]
4/2
09:51 am
tak
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Global Clinical Trials Review 2024, Featuring Takeda Pharmaceutical, JCR Pharmaceuticals, GC Corp, RegenxBio, Sangamo Therapeutics and Generium [Yahoo! Finance]
Low
Report
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Global Clinical Trials Review 2024, Featuring Takeda Pharmaceutical, JCR Pharmaceuticals, GC Corp, RegenxBio, Sangamo Therapeutics and Generium [Yahoo! Finance]
4/1
02:35 am
tak
Aculys Pharma Announces Appointment of Hidemasa Tanigaki as New CEO [Yahoo! Finance]
Medium
Report
Aculys Pharma Announces Appointment of Hidemasa Tanigaki as New CEO [Yahoo! Finance]
3/28
06:09 pm
tak
Global Convalescent Plasma Therapy Market to Grow at a CAGR of 11.8% from 2023 to 2024 [Yahoo! Finance]
Medium
Report
Global Convalescent Plasma Therapy Market to Grow at a CAGR of 11.8% from 2023 to 2024 [Yahoo! Finance]
3/27
09:08 am
tak
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE [Yahoo! Finance]
Low
Report
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE [Yahoo! Finance]
3/27
08:56 am
tak
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
Low
Report
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
3/27
08:53 am
tak
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
Low
Report
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
3/26
07:12 pm
tak
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting [Yahoo! Finance]
Low
Report
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting [Yahoo! Finance]
3/26
07:07 pm
tak
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
Low
Report
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
3/26
08:25 am
tak
Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP) [Yahoo! Finance]
Low
Report
Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP) [Yahoo! Finance]
3/26
08:00 am
tak
Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Low
Report
Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
3/19
12:32 pm
tak
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL [Yahoo! Finance]
Low
Report
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL [Yahoo! Finance]
3/19
12:20 pm
tak
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
Low
Report
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
3/15
12:56 pm
tak
Takeda's 'In Their Shoes' Program Sheds Light on IBD Challenges in South Africa
Low
Report
Takeda's 'In Their Shoes' Program Sheds Light on IBD Challenges in South Africa
3/13
08:00 am
tak
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
Low
Report
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia